Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice

Pharmaceutical Research

Volumn 32, Issue 2, 2015, Pages 430-444

  Freitag, Angelika J ^a   Shomali, Maliheh ^b   Michalakis, Stylianos ^a   Biel, Martin ^a   Siedler, Michael ^c   Kaymakcalan, Zehra ^c   Carpenter, John F ^d   Randolph, Theodore W ^b   Winter, Gerhard ^a   Engert, Julia ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UCB 450   (United States)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Immunogenicity; Monoclonal antibody; Protein aggregates; Protein particles; Wild typemice

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOGENETICS; IMMUNOLOGY; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; FEMALE; IMMUNOGENETIC PHENOMENA; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 84926367775     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1472-6     Document Type: Article

References (55)

1. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002;324(1):14-30.
2. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1-2):1-9. Epub 2008/02/16.
3. Tamilvanan S, Raja NL, Sa B, Basu SK. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J Drug Target. 2010;18(7):489-98.
4. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2003;18(7):1257-9.
5. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100(2):354-87.
6. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685-98.
7. Swanson SJ, editor. Immunogenicity of Therapeutic Proteins. Hoboken: Wiley; 2010.
8. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 2007;25(5):555-61. Epub 2007/05/08.
9. Schellekens H. Immunogenicity of protein therapeutics, or how to make antibodies without T-cells. Inflamm Res. 2007;56:S351-S2.
10. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20:3-9.
11. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251:4-9.
12. Schellekens H. The immunogenicity of biopharmaceuticals. Neurology. 2003;61(9):S11-S2.
13. Schellekens H. Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia. Curr Med Res Opin. 2003;19(5):433-4.
14. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24(11):1720-40.
15. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity concerns of therapeutic protein products part 1 considering consequences of the immune response to a protein. Biopharm Int. 2004;17(11):22-+.
16. Rosenberg A, editor. FDA Perspective on Immunogenicity Testing-A Risk Based Analysis. Bethesda, MD; 2003.
17. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS. Persistence of neutralizing antibodies after discontinuation of IFN beta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2006;12(3):247-52.
18. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28(11):482-90.
19. Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw. 1999;10(3):413-22.
20. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18(3):473-80.
21. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 1993;16 Suppl 3:155-65.
22. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2007;68(13):977-84.
23. Ring J, Stephan W, BrendelW. Anaphylactoid reactions to infusions of plasma-protein and human-serum albumin - role of aggregated proteins and of stabilizers added during production. Clin Allergy. 1979;9(1):89-97.
24. Christian CL. Studies of aggregated γ-globulin: II effect in vivo. J Immunol. 1960;84(1):117-21.
25. Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 2004;61(3):108-20.
26. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther. 2003;5(2):172-9.
27. Hermeling S, Aranha L, Damen JMA, Slijper M, Schellekens H, Crommelin DJA, et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon Alpha2b. Pharm Res. 2005;22(12):1997-2006.
28. Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha ) in normal and transgenic mice. Pharm Res. 1997;14(10):1472-8.
29. Van Beers MMC, Gilli F, Schellekens H, Randolph TW, Jiskoot W. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci. 2012;101(1):187-99.
30. Hesterberg LK, Seefeldt MB, Carpenter JF, Randolph TW. High-Hydrostatic pressure refolding of proteins. Genet Eng News. 2005;25(4):46-7.
31. Fradkin AH, Carpenter JF, Randolph TW. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci. 2009;98(9):3247-64.
32. van Beers MMC, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res. 2010;27(9):1812-24.
33. Fradkin AH, Carpenter JF, Randolph TW. Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J Pharm Sci. 2011;100(11):4953-64.
34. Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28(10):2379-85.
35. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods (San Diego, CA, U S). 2005;36(1):3-10.
36. Schoeneich C. Light-induced oxidation and aggregation of proteins: potential immunogenicity consequences. Workshop on Protein Aggregation and Immunogenicity; July, 2010; Breckenridge, CO, July 20-22, 2010
37. WangW. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289(1-2):1-30.
38. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock. 2004;22(5):460-6.
39. PhEur 2.2.1. Clarity and degree of opalescence of liquids. European Directorate for the Quality of Medicine (EDQM). 7th edition; 2011.
40. PhEur 0169. Monograph " Water for injections ". European Directorate for the Quality of Medicine (EDQM). 7th edition; 2011.
41. Dintzis HM, Dintzis RZ, Vogelstein B. Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci U S A. 1976;73(10):3671-5.
42. Martin RM, Brady JL, Lew AM. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods. 1998;212(2):187-92.
43. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488-96.
44. Freitag AJ, Wittmann K, Winter G, Myschik J. The preparative use of flow field-flow fractionation. LCGC Europe. 2011;24(3):134.
45. Shomali M, Freitag A, Engert J, Siedler M, Kaymakcalan Z, Winter G, et al. Antibody responses in mice to particles formed from adsorption of a murine monoclonal antibody onto glass microparticles. J Pharm Sci. 2014;103(1):78-89.
46. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164(12):6166-73.
47. Coutelier JP, Van der Logt JTM, Heessen FWA, Vink A, Van Snick A. Virally induced modulation of murine IgG antibody subclasses. J Exp Med. 1988;168(6):2373-8.
48. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature (London). 1988;334(6179):255-8.
49. Ramakrishna C, Ravi V, Desai A, Subbakrishna DK, Shankar SK, Chandramuki A. T helper responses to japanese encephalitis virus infection are dependent on the route of inoculation and the strain of mouse used. J Gen Virol. 2003;84(6):1559-67.
50. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol. 1997;158(5):2278-84.
51. Hermeling S, Schellekens H, Maas C, Gebbink MFBG, Crommelin DJA, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 2006;95(5):1084-96.
52. Vollmar D. Immunologie - Grundlagen und Wirkstoffe. 1st ed. München, Frankfurtam Main: Wissenschaftliche Verlagsgesellschaft mbH Stuttgart; 2005.
53. Haley PJ. Species differences in the structure and function of the immune system. Toxicology. 2003;188(1):49-71.
54. Filipe V, Que I, Carpenter J, Löwik C, Jiskoot W. In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice. Pharm Res. 2014;31(1):216-27.
55. Kijanka G, Prokopowicz M, Schellekens H, Brinks V. Influence of aggregation and route of injection on the biodistribution of mouse serum albumin. PLoS One. 2014;9(1):1-9.